T he functional specializations of dendritic cells (DCs) and monocytes-macrophages have been a topic of much investigation, with recent focus on their developmental lineages as a way of understanding the relationships between these two cell types. Under steady state conditions, monocytes act as versatile cells that can convert into a variety of tissue-resident and lymphoid organ macrophage subsets. Under these same conditions, conventional DCs (cDCs) derive from a specialized precursor that shares a common progenitor to, but is distinct from, monocytes (1, 2) . This lineage separation is paralleled by a divergence of functional specializations. The monocyte-macrophage lineage is specialized for robust Ag scavenging and secretion of inflammatory cytokines, but their capacity to convert internalized Ag into peptide-MHC complexes is poor. In contrast, cDCs are specialized for the efficient conversion of small amounts of captured Ag into peptide-MHC complexes, migration to T cell zones, and initiation of T cell responses (3, 4) .
During inflammation, the plasticity of monocytes may also extend to the formation of certain subsets of dendritic cells (DCs), making it difficult to distinguish between these two lineages. Monocyte-derived DCs include TNF/iNOS-producing DCs and other inflammatory DCs (iDCs) described under microbial infec-tions or adjuvant-induced peritonitis (1, (5) (6) (7) (8) . Monocyte-derived iDCs are characterized as DCs based on the expression of surface markers characteristic of cDCs in the spleen and lymph nodes, namely high surface expression of CD11c, as well as MHC-II and costimulatory molecules. Some iDCs were found to be dispensable for Ag presentation and T cell priming (9) , whereas other iDCs were proposed to contribute to T cell stimulation (8, (10) (11) (12) . Given the variety in inflammatory settings under which these iDCs arise, it is unclear whether the various iDCs reported represent related populations with common functional properties or they encompass a spectrum of different monocyte-derived cell types.
Because most studies describing conversion of monocytes into iDCs rely on processes that last several days or weeks, we sought to evaluate the conversion of monocytes into iDCs in vivo under conditions that induce potent Ag-specific immunity. We studied the response of mice to anti-CD40 treatment, which has proven efficacy to prime effective T cell responses in experimental animals (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) and has shown significant clinical potential (28) (29) (30) . We found that induction of systemic inflammation in mice with an activating Ab against CD40 uniformly induced surface CD11c expression on Ly6C Hi monocytes. These cells also expressed MHC class II (MHC-II) and costimulatory molecules typically associated with DC-like phenotypes ascribed to iDCs. However, these Ly6C Hi -CD11c Hi monocyte-derived iDCs share functional properties with their Ly6C Hi -CD11c Neg precursors, not with Ly6C Neg -CD11c Hi cDCs. In addition, this phenotypic change accompanies an increase in endocytic capacity, highlighting their activated monocyte phenotype. After 3-4 d, this Ly6C Hi -CD11c Hi monocyte-derived population reverts to a surface phenotype characteristic of monocytes, further supporting the continuity of the DC-independent lineage.
(CD40 KO) were obtained from The Jackson Laboratory. Mice were housed under specific-pathogen-free conditions and maintained in compliance with institutional and federal regulatory guidelines. anti-CD40 mAb mediated inflammation was achieved by i.p. injection of 100 mg FGK4.5 mAb (Bio X Cell) or clone IC10 (LEAF grade, BioLegend). Rat IgG2a isotype control (LEAF grade, BioLegend) was used for control injections. Each injection of Ab (used to induce inflammation) or Ag (to study endocytosis or Ag presentation to T cells), contained undetectable levels of endotoxin, lower than 0.126 EU (∼13 pg) based on LAL test (Cambrex).
Cells
Unless otherwise specified, all cells were washed and resuspended in PBE (PBS with 0.5% BSA, endotoxin free; Equitech-Bio; 1 mM EDTA). Spleens were digested with Liberase Blendzyme 2 (Roche Diagnostics) for 15 min in PBS at 21˚C, passed through a 40-mm cell strainer, treated with ACK Buffer (Lonza) to remove red cells, and resuspended in PBE. For purification of cells for in vitro Ag presentation experiments or for transfer experiments, splenocytes were first enriched by magnetic negative depletion with biotinylated Abs against CD19 (MB19.1), CD3 (145-2C11), NK1.1 (PK136), Ly-6G(1A8), and erythroid cell marker (TER-119) Abs (eBioscience or BioLegend), followed by enrichment using the EasySep Biotin Selection Kit (StemCell Technologies). Cells were subsequently sorted on a Dako MoFlo. Postsort analysis confirmed purity of .96% and viability of .95%. OT-I CD8 + or OT-II CD4 + T cells were isolated from the lymph nodes and spleens of OT-I/RAG1 knockout (KO) or OT-II/ RAG1 KO mice by disruption through a 40-mm cell strainer, followed by negative selection using mouse CD8 + T cell or mouse CD4 + T cell enrichment kit, respectively (StemCell Technologies). Enriched T cells were pulsed with 0.5 mM CFSE (Invitrogen) for 5 min, washed twice, and resuspended in complete RPMI 1640.
Monocyte transfer experiments
Ly6C Hi monocytes (as identified in Fig. 1A) were purified from spleens of CD45.1 mice by cell sorting. Purified cells (5.0 3 10 5 ) were injected i.v. into mice that were injected either with 100 mg anti-CD40 mAb or with control IgG or PBS as negative controls 5 min after cell transfer. At various time points after transfer, spleens were analyzed by flow cytometry, and the phenotypes of the endogenous (CD45.2) and transferred (CD45.1) cells were assessed.
Endocytosis assays
Soluble GFP protein was prepared as described previously (31) . The construct in pET-28 vector (Novagen) in BL21 Escherichia coli (Novagen) was grown in TB media (Invitrogen) at 37˚C to a density of ∼0.1 absorbance units at 600 nm, then at 24˚C for 16 h with 1 mM isopropyl b-Dthiogalactoside (Sigma). Cells were lysed with lysozyme, sonication, and freeze-thaw cycles, and the his-tagged protein was affinity purified on Ni-Sepharose (Pharmacia). The resulting protein was further purified by ion exchange with Q-Sepharose (Pharmacia). The resulting protein had ,1.26 EU/mg of endotoxin (,∼125 pg/mg) by LAL test (Cambrex). For in vivo soluble Ag endocytosis assays, 2 mg GFP was injected i.v., and 30 min later splenocytes were collected and analyzed for Ag capture as compared with a similarly treated mouse not injected with Ag. Endotoxin-free OVA (prepared as described below for Ag-presentation assays) at 10 mg/ml in PBS was labeled using florescein-5-isothiocyanate (Invitrogen) according to the manufacturer's instructions. Excess unincorporated fluorescein was removed over a Sephadex G-25 column (GE Healthcare) followed by several buffer exchanges with PBS using an Amicon Ultra-4 centrifugal filter device (Millipore) and filtration over a Polymixin-B-Sepharose column (Pierce). For endocytosis assays, mice were injected with 900 mg FITC-OVA, and 20 min later spleens were analyzed by flow cytometry to detect FITC-OVA uptake. Fluorescent particulate Ag was prepared by incubating 1.8 mm streptavidin-coated polystyrene microbeads (Spherotech) at 2.8 3 10 9 /ml with 10 mg/ml Fluorescein-biotin (Invitrogen) in PBS for 30 min and washed in PBE. For 2-mm particle uptake assays, 1.4 3 10 8 particles were injected i.v. and 60 min later spleenocytes were collected and analyzed for Ag capture. Cells were also stained with PE-conjugated anti-fluorescein (Invitrogen) to distinguish cells that completely internalized particles (fluorescein positive, PE negative), from cells with particles stuck to their surface (fluorescein positive, PE positive). For 5-mm particle endocytosis assays, 0.8 3 10 8 Fluoresbrite YG carboxylate microspheres (Polysciences) were 
Ag-presentation assays
OVA protein (grade IV; Sigma) was purified to remove any potential endotoxin contamination by ion exchange using Q-Sepaharose (Pharmacia) as described previously (31) . To assay presentation of Ag captured by cells in vivo, 1.0 mg OVA protein was injected i.v. into mice, and 30 min later cells were purified by cell sorting as described above. Various numbers of APCs were cocultured with 50,000 CFSE-labeled OT-I CD8 + T cells or OT-II CD4 + T cells in U-bottom 96-well plates. Sixty hours later, T cell proliferation was assessed using flow cytometry to measure the dilution of CFSE accompanying each T cell division. Cells were cultured in RPMI 1640 (Life Technologies) with 10% heat-inactivated FBS (Invitrogen), nonessential amino acids, 110 mg/ml sodium-pyruvate, 2 mM L-glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin (Life Technologies), and 100 mM mercaptoethanol (Sigma) in a 5% CO 2 37˚C incubator.
Monocyte tracking with beads
Experiments were performed as previously described (25, 29) . Mice were injected i.v. with 50 ml (2.3 3 10 9 ) Fluoresbrite Carboxylate YG 1.0-mm microspheres (Polysciences) resuspended in PBS. At various times after bead injection, mice were injected with 100 mg anti-CD40 mAb i.p. or with control IgG or PBS as negative controls. At various time points after injection, splenocytes were purified and the cells containing the participles were analyzed by flow cytometry.
Flow cytometry
Cells were preincubated with 10 mg/ml 2.4G2 mAb (Bio X Cell) for 15 min at 4˚C in PBE, incubated with mAb conjugates for 30 min at 4˚C, washed in PBE, and resuspended in PBE with 0.5 mg/ml 7-aminoactinomycin-D (Invitrogen) 10 min before analysis. Data were collected on a FACSCanto (BD Biosciences) and analyzed with FlowJo software (TreeStar). Mean 6 SD of multiple experiments was calculated using Prism software (GraphPad Software) Abs: TCR-b (H57-597), CD19 (6D5), B220 (RA3-62B), NK1.1 (PK136), Ly-6G (1A8), Siglec-H (440c), CD11b (M1/70), CD11c (N418), Ly-6C (HK1.4), CD115 (AFS98), F4/80 (BM8), Mac-3 (M3/84), CD14 (Sa14-2), Mac-2 (m3/38), CD43 (1B11), CD45.1 (A20), CD45.2 (104), CD8a (53-6.7), CD4 (GK1.5), CD86 (GL-1), CD80 (16-10A1), IA/E (M5/114.15.2), H2-Kb (AF6-88.5), CD40 (HM40-3), and isotype control in corresponding fluors (mouse IgG2a, Rat IgG1, Rat IgG2a, Rat IgG2b, Armenian Hamster IgG, Armenian Hamster IgM) were purchased from eBioscience or BioLegend.
Intracellular TNF-a analysis
Mice were injected with 100 mg anti-CD40 mAb i.p., and 40 h later splenocytes were isolated and cultured in complete RPMI 1640 in the presence of media alone, 200 ng/ml LPS (from Salmonella typhimurium; Sigma), 5 mg/ml anti-CD40 mAb, or 5 3 10 7 /ml heat-killed Listeria (strain 10402S), and 5 mg/ml brefeldin A (Invitrogen). Sixty minutes later, cells were first stained for surface markers (see flow cytometry above) and then for intracellular TNF-a using Cytofix/Cytoperm (BD Biosciences) according to the manufacturer's instructions. TNF-a was detected using biotinanti-TNF-a (MP6-XT22; BioLegend), followed by streptavidin-PE (Invitrogen). Biotin-rat IgG1 (BioLegend) was used as an isotype control.
Confocal microscopy
Spleens were immersed in OCT media (Tissue-Tek) and frozen in an isopentane-liquid nitrogen bath; 10-mm cryosections were fixed in acetone for 5 min at 220˚C. All subsequent steps were performed at room temperature. Sections were dried for 1 h, rehydrated in PBS for 10 min, and blocked with 5% goat serum and 5 mg/ml anti FcR-mAb (2.4G2; Bio X Cell). T cells were stained with 2 mg/ml rabbit anti-CD3 (Dako) for 1 h, followed by 0.16 mg/ml HRP conjugated anti-rabbit (Jackson Immunoresearch) for 1 h, and detected using the cyanine-3 system (Perkin Elmer) as directed. Dendritic cells were stained with 1.67 mg/ml Alexa647-conju- gated CD11c (N418; BioLegend) for 1 h, and monocytes were stained with 0.6 mg/ml FITC-conjugated anti-Ly6C (HK1.4; Biolegend) for 1 h followed by 2 mg/ml Alexa488-conjugated goat anti-fluorescein (Invitrogen) for 1 h. Control stains were performed with normal rabbit serum or isotype controls labeled with Alexa647 or FITC. Sections were mounted with Prolong Gold (Invitrogen) and imaged with a Zeiss Plan Apochromat 103 0.45NA objective on a Zeiss LSM510 microscope.
Results
Ly6C Hi -CD11c Hi monocytes accumulate in the spleen of mice after treatment with anti-CD40 mAb
We focused on the two major populations of monocytes in the spleen: Ly6C Hi -CD11c Neg monocytes and Ly6C Neg -CD11c Low monocytes ( Fig. 1A) . Unlike monocytes, cDCs are Ly6C Neg and express high levels of CD11c, a marker that is typically used to identify these cells ( Fig. 1A) . To analyze the behavior of monocytes and the potential formation of iDCs in vivo under conditions that induce strong Ag-specific immunity, we studied mice treated with an agonistic Ab against CD40, which has proven efficacy to prime effective T cell responses in experimental animals (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . We found that induction of systemic inflammation in mice with an anti-CD40 mAb induced CD11c expression on Ly6C Hi monocytes in the spleen, reaching levels comparable to cDCs in the same mouse within 40 h (Fig. 1B, 1C) . The same induction of CD11c expression on Ly6C Hi cells was obtained with two different clones of agonistic anti-CD40 mAb, whereas this conversion did not occur in mice that lacked CD40 (Supplemental Fig. 1A) .
These Ly6C Hi -CD11c Hi cells are also apparent in the CD11b versus CD11c plots commonly used to detect the appearance of iDCs (Supplemental Fig. 1B, 1C ). This Ly6C Hi -CD11c Hi -CD11b Hi phenotype is typical of iDCs described under various inflammatory stimuli. In mice treated with anti-CD40 for 40 h, we could identify four populations for further comparison: Ly6C Hi monocytes, Ly6C neg monocytes, Ly6C Hi -CD11c Hi cells, and CD11b + cDCs (Fig. 1C) . A comparison of these four populations shows that Ly6C Hi -CD11c Hi cells and CD11b + cDCs express similar levels of CD11c, whereas Ly6C neg monocytes express low levels of CD11c and Ly6C Hi monocytes do not express CD11c (Supplemental Fig. 1D ). Although similar populations of Ly6C Hi -CD11c Hi cells could be detected in other organs after anti-CD40 treatment (Supplemental Fig. 1E ) we focused our analysis on spleen-derived monocytes because of the abundance of these cells and to be able to establish a direct comparison with the wellcharacterized cDCs from that organ.
In addition to high levels of CD11c, these Ly6C Hi -CD11c Hi cells also expressed MHC-II and costimulatory molecules at levels similar to cDCs from the spleen of the same mouse, which is another surface phenotype typical of iDCs ( Fig. 2A ). Although these Ly6C Hi -CD11c Hi cells shared some surface characteristics with cDCs, the expression levels of other markers such as F4/80, Mac-2, Mac-3, CD14, and CD115 remained closer to their Ly6C Hi monocyte precursors than to cDCs ( Fig. 2A) . The Ly6C neg monocytes in the spleen of the same animals retained lower MHC-II expression under the same conditions (Fig. 2B) . These results show that treatment of mice with anti-CD40 mAb induces the appearance of a population of Ly6C Hi -CD11c Hi cells that shares surface markers with both cDCs and monocytes. For simplicity we will continue to refer to these monocyte-derived Ly6C Hi -CD11c Hi cells as iDCs, although this population likely differs from previously described inflammatory monocyte-derived iDCs, as shown below.
Spleen Ly6C Hi -CD11c Hi cells derive from monocytes
The appearance of Ly6C Hi cells expressing high levels of CD11c following injection of anti-CD40 suggested that Ly6C Hi -CD11c Hi cells were the result of upregulation of CD11c on Ly6C Hi -CD11c Neg monocytes in the spleen. However, these results could not exclude the possibility that the Ly6C Hi -CD11c Neg population was disappearing and simultaneously replaced by unrelated populations with increasingly higher levels of CD11c. To distinguish between these alternatives, we used a bead-labeling protocol for tracking monocytes in situ (32) (33) (34) . One hour after injection, beads were associated primarily with Ly6C Hi and Ly6C Neg monocytes, and to a lesser degree with DCs (Fig. 3A, Supplemental Fig.  2 ). When control-treated mice (uninflamed) were analyzed 24 or 40 h after injection of beads without any inflammatory treatment, beads were associated almost exclusively with Ly6C Neg monocytes, and there were almost no more bead-associated Ly6C Hi monocytes (Fig. 3B, Supplemental Fig. 2) , which was previously shown to reflect the conversion of the Ly6C Hi to Ly6C Neg monocytes (34) (35) (36) . However, when mice were additionally treated with anti-CD40 only 15 min after bead injection, beadassociated Ly6C Hi -CD11c Hi cells could be identified easily, indicating the conversion of monocytes to Ly6C Hi -CD11c Hi cells (Fig.  2B ). In these experiments, both Ly6C hi monocytes and Ly6C neg monocytes contained beads at the time of anti-CD40 administration, making it possible that both monocyte populations contributed to the Ly6C Hi -CD11c Hi cells.
To investigate the contribution of Ly6C Neg monocytes to the Ly6C Hi -CD11c Hi population, mice were injected with beads and then rested for 24 h to allow the bead-labeled Ly6C hi monocytes to convert to bead-labeled Ly6C neg monocytes, as described previously (34) (Fig. 3C, Supplemental Fig. 2 ). These mice with beads almost exclusively limited to Ly6C neg monocytes were then injected with anti-CD40. Forty hours after treatment, beads were also found within Ly6C Hi -CD11c Hi cells, suggesting that Ly6C neg monocytes contribute to the formation of the Ly6C Hi -CD11c Hi population (Fig. 3D ).
Because bead tracking in situ cannot selectively label the Ly6C hi monocytes without additional manipulations such as clodronate liposomes (33) , we sorted Ly6C Hi monocytes from CD45.1 mice and adoptively transferred them i.v. into syngeneic CD45.2 recipients (Fig. 3E) . When recipient mice were control treated, we observed the subsequent conversion of these transferred Ly6C Hi monocytes into Ly6C Neg monocytes (Fig. 3F) , as described previously (34) (35) (36) . In contrast, when inflammation was induced with anti-CD40 after adoptive transfer, we observed upregulation of CD11c on the transferred Ly6C Hi monocytes, which paralleled the induction of CD11c expression on the endogenous Ly6C Hi population in the recipient (Fig. 3F) . These results indicate that the Ly6C Hi -CD11c Hi cells formed under inflammation induced by anti-CD40 treatment were a result of upregulation of CD11c on splenic CD11c Neg monocytes. To evaluate the role of CD40 on the responding splenic monocytes, we prepared mixed bone-marrow chimeras between wild type and CD40 2/2 mice (Supplemental Fig. 3 ). We found that ligation of CD40 on bone marrow-derived cells is required for the induction of Ly6C Hi -CD11c Hi cells, and the formation of this population is further enhanced when CD40 is also expressed on somatic cells (Supplemental Fig. 3A ). In addition, wild type Ly6C hi monocytes transferred into CD40 2/2 recipients could not be induced to form Ly6C Hi -CD11c Hi cells, indicating that CD40 ligation on the monocytes alone is insufficient, but a variety of cell types contribute to the inflammatory response to anti-CD40 (Supplemental Fig. 3B ).
Ly6C Hi -CD11c Hi cells functionally resemble activated monocytes
The apparent activation of Ly6C Hi monocytes in mice treated with anti-CD40 led to a surface phenotype with similarities to both cDCs and their Ly6C Hi monocyte precursors; therefore, we wanted to determine whether these iDCs exhibit functional characteristics of cDCs. To this end, we compared the endocytic capacity and Ag-presenting capacities of Ly6C Hi monocytes, iDCs (Ly6C Hi -CD11c Hi ), and cDCs, all of them isolated from the same mice treated with anti-CD40. To examine their phagocytic capacity in situ, mice were injected i.v. with 2-mm fluorescent particles. As expected, Ly6C Hi monocytes showed a higher phagocytic capacity compared with cDCs ( Fig. 4A ). In these same mice, the Ly6C Hi -CD11c Hi cells also demonstrated a higher phagocytic capacity than did cDCs, similar to their monocyte precursors. Interestingly, this phagocytic capacity was enhanced compared with their monocyte precursors, suggesting that activation of this function accompanied their phenotypic transformation (Fig. 4A ). When similar experiments were performed using larger (5 mm) fluorescent beads, we found that Ly6C Hi monocytes could still internalize these large particles, which could not be internalized by cDCs (Fig. 4B) . In contrast to cDCs, the Ly6C Hi -CD11c Hi cells exhibited a similar or enhanced ability to capture large particles compared with their monocytic precursors (Fig. 4B) . A similar result was also observed after injection of soluble proteins as an endocytic probes (GFP [ Fig. 4C ] or FITC-OVA [ Fig. 4D] ). Ly6C Hi monocytes exhibited a markedly higher endocytic activity than cDCs, whereas Ly6C Hi -CD11c Hi cells exceeded both of these populations (Fig. 4C, 4D) .
Having established the endocytic capacity of these three cell populations, we next evaluated their capacity to present the internalized Ags to T cells (Fig. 5A ). To this end, mice treated with anti-CD40 were injected i.v. with 1 mg OVA, and 30 min later the spleen cDCs, Ly6C Hi -CD11c Hi (iDCs), and Ly6C Hi -CD11c Neg (Ly6C Hi monocytes) cells were isolated by cell sorting and cocultured with OT-I or OT-II T-cells. We found that, despite their comparatively weaker endocytic capacity (Fig. 4) , cDCs were much more effective than Ly6C Hi -CD11c Hi or Ly6C Hi -CD11c Neg monocytes in presenting Ag on both MHC-I and MHC-II and stimulating cognate T cells. cDCs induced strong T cell proliferation, even at low cDC:T cell ratios. Under these same conditions, in which the Ly6C Hi -CD11c Hi and Ly6C Hi -CD11c Neg monocytes had shown high levels of Ag capture (Fig. 4) , both populations induced little, if any, CD4 + or CD8 + T cell proliferation (Fig. 5A ). In agreement with their high scavenging and poor Ag presentation activities, Ly6C Hi -CD11c Hi monocyte-derived cells were found predominantly in the red pulp of the spleen of inflamed mice, but they were essentially absent from T cell areas, in contrast with cDCs ( Fig. 5B ). Finally, we examined the ability of each population to produce inflammatory cytokine TNF-a after further stimulation. Ly6C Hi -CD11c Hi cells, cDCs, and resident spleen monocytes all had the capacity to produce TNF-a upon restimulation in vitro (Supplemental Fig. 4 ). In conclusion, although the surface phenotype of Ly6C Hi -CD11c Hi monocyte-derived cells shares some markers with cDCs, they share other surface markers, similar scavenging, and poor Ag-presenting characteristics of their monocyte precursors, and they consequently do not appear to acquire functional properties associated with cDCs.
Ly6C Hi -CD11c Hi cells ultimately convert into Ly6C neg monocytes
We considered the possibility that the conversion of Ly6C Hi monocytes to a cDC-like phenotype could take longer, and we consequently followed the fate of these cells at later time points after delivery of anti-CD40 stimulation. We found that up to 5 d after injection of anti-CD40, a decrease in Ly6C Hi -CD11c Hi cells correlated with an increase in Ly6C Neg -CD11c Neg monocytes (Fig. 6A ). To determine whether this reduction in the numbers of Ly6C Hi -CD11c Hi cells could indicate their further conversion into cDC-like population, we performed adoptive transfer experiments for longer periods, after Ly6C Hi -CD11c Hi cells had apparently disappeared. Interestingly, the transferred Ly6C Hi monocytes, which convert into Ly6C Hi -CD11c Hi cells after 24 to 40 h (Fig.  3F ), subsequently converted into Ly6C Neg -CD11c Neg monocytes (Fig. 6B) ; this is similar to the fate of Ly6C Hi monocytes in the steady state ( Fig. 3F) (34) (35) (36) . In addition, when we mapped the fate of these cells using the bead tracking techniques as in Fig. 3B , we also found that the Ly6C Hi -CD11c Hi cells had converted into Ly6C Neg monocytes at later time points (Fig. 6C ).
Discussion
Our results indicate that under sterile systemic inflammatory conditions induced with anti-CD40, Ly6C Hi monocytes induce CD11c expression together with other surface markers typically associated with their acquisition of DC-like phenotype. However, such monocyte-derived CD11c Hi cells retain many characteristics of monocytes, including several surface markers, a high endocytic capacity, and inefficient conversion of internalized Ags into peptide-MHC complexes for T cell stimulation. In addition, these cells follow the fate of their monocytic lineage, ultimately converting into Ly6C Neg monocytes. These findings demonstrate that the upregulation of CD11c by monocytes and the conversion to DCs can be distinct processes; therefore, under certain inflammatory conditions, the expression of CD11c, MHC-II, and costimulatory molecules is insufficient to identify a population with similar properties as cDCs. Although not observed in this study, the expression of CD11c on other cell types, such as NK cells (37) (38) (39) , may also be subject to regulation under inflammatory conditions.
The results presented in this and previous studies have shown that the material scavenged by monocyte and some monocytederived iDCs is apparently not presented to T cells efficiently (3, 9, 40) . Given the abundance of iDCs and their vigorous scavenging capacity, it is important to establish the fate of such scavenged material, which can be transferred to other cell types, including Ag-presenting cDCs, even as preformed pMHC complexes (3, (41) (42) (43) (44) (45) (46) .
In prior studies describing monocyte-derived DCs, it has not been easy to distinguish between fully converted monocytes and functional DCs (47, 48) . In previously described models relying on peritonitis induced by long-term effects of emulsified adjuvants or microbial infections, it has been difficult to establish a direct precursor-product relationship between monocytes and cDCs without ruling out alterations in the properties of cDC or pre-DC progenitors (7, 48) . A recent study has shown that components from Gram-negative bacteria such as LPS can induce the conversion of blood monocytes into Ag-presenting monocyte-derived DCs migrating to lymph nodes (8) . Given that conversion of monocytes into Ag-presenting DCs does not appear to be complete under certain inflammatory conditions with similar components derived from Gram-negative bacteria (49) or under sterile inflammation as reported in this study, it will be important to define the conditions that induce the full conversion of monocytes into iDCs capable of T cell stimulation.
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